MA30201B1 - Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1 - Google Patents
Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1Info
- Publication number
- MA30201B1 MA30201B1 MA30932A MA30932A MA30201B1 MA 30201 B1 MA30201 B1 MA 30201B1 MA 30932 A MA30932 A MA 30932A MA 30932 A MA30932 A MA 30932A MA 30201 B1 MA30201 B1 MA 30201B1
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- hydroxysteroid dehydrogenase
- inhibitors
- niddm
- triazolic derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Des dérivés triazoliques de formule structurale I sont des inhibiteurs sélectifs de 11(beta)-hydroxystéroïde déhydrogénase-1. Ces composés sont utiles pour le traitement du diabète, notamment du diabète non insulinodépendant (NIDDM), de l'hyperglycémie, de l'obésité, de la résistance à l'insuline, de la dyslipidémie, de l'hyperlipidémie, de l'hypertension, du syndrome métabolique et d'autres symptômes associés au NIDDM.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72872305P | 2005-10-20 | 2005-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30201B1 true MA30201B1 (fr) | 2009-02-02 |
Family
ID=37963190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30932A MA30201B1 (fr) | 2005-10-20 | 2008-05-16 | Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7981910B2 (fr) |
EP (1) | EP1940393B1 (fr) |
JP (1) | JP5036722B2 (fr) |
KR (1) | KR20080059236A (fr) |
CN (2) | CN103724335A (fr) |
AU (1) | AU2006304434B2 (fr) |
BR (1) | BRPI0617501A2 (fr) |
CA (1) | CA2625871C (fr) |
CR (1) | CR9931A (fr) |
EC (1) | ECSP088384A (fr) |
IL (1) | IL190436A0 (fr) |
MA (1) | MA30201B1 (fr) |
NI (1) | NI200800069A (fr) |
NO (1) | NO20082278L (fr) |
RU (1) | RU2008119842A (fr) |
SV (1) | SV2009002876A (fr) |
WO (1) | WO2007047625A2 (fr) |
ZA (1) | ZA200802104B (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7834178B2 (en) | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
CN101663033B (zh) * | 2007-04-18 | 2013-01-16 | 默沙东公司 | 作为smo拮抗剂的三唑衍生物 |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
FR2942797B1 (fr) * | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
CA2771278A1 (fr) | 2009-08-26 | 2011-03-03 | Sanofi | Nouveaux hydrates de fluoroglycoside heteroaromatiques cristallins, substances pharmaceutiques comprenant ces composes et leur utilisation |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
EP2760862B1 (fr) | 2011-09-27 | 2015-10-21 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
CN104910083A (zh) * | 2015-07-13 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | 烷氧苯基三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途 |
CN105001170A (zh) * | 2015-07-13 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途 |
CN104961696A (zh) * | 2015-07-13 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 一类卤苯三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途 |
CN104910084A (zh) * | 2015-07-13 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | 末端胺基取代的三氮唑亚砜类化合物、其制备方法及其用途 |
CN105001171A (zh) * | 2015-07-13 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 一类硝基苯三氮唑亚砜类11β-HSD1抑制剂及其用途 |
CN105017170A (zh) * | 2015-07-13 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 一类腈基苯三氮唑亚砜类11β-HSD1抑制剂及其用途 |
CN104961697A (zh) * | 2015-07-13 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 末端卤素取代的三氮唑亚砜类化合物、其制备方法及其用途 |
CN104987313A (zh) * | 2015-07-13 | 2015-10-21 | 佛山市赛维斯医药科技有限公司 | 一类末端取代的三氮唑亚砜类化合物、其制备方法及其用途 |
CN104987312A (zh) * | 2015-07-13 | 2015-10-21 | 佛山市赛维斯医药科技有限公司 | 一类胺基苯三氮唑亚砜类11β-HSD1抑制剂及其用途 |
CN104974103A (zh) * | 2015-07-14 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途 |
CN104926745A (zh) * | 2015-07-14 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途 |
CN105001152A (zh) * | 2015-07-19 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 一类二甲胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
CN105017135A (zh) * | 2015-07-19 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 一类二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途 |
TWI802591B (zh) * | 2017-09-14 | 2023-05-21 | 日商第一三共股份有限公司 | 具有環狀構造的化合物 |
US11917514B2 (en) | 2018-08-14 | 2024-02-27 | Rapidsos, Inc. | Systems and methods for intelligently managing multimedia for emergency response |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
-
2006
- 2006-10-16 BR BRPI0617501-5A patent/BRPI0617501A2/pt not_active IP Right Cessation
- 2006-10-16 CN CN201410039746.3A patent/CN103724335A/zh active Pending
- 2006-10-16 AU AU2006304434A patent/AU2006304434B2/en not_active Ceased
- 2006-10-16 JP JP2008536728A patent/JP5036722B2/ja not_active Expired - Fee Related
- 2006-10-16 RU RU2008119842/04A patent/RU2008119842A/ru not_active Application Discontinuation
- 2006-10-16 KR KR1020087009369A patent/KR20080059236A/ko not_active Application Discontinuation
- 2006-10-16 WO PCT/US2006/040459 patent/WO2007047625A2/fr active Application Filing
- 2006-10-16 NI NI200800069A patent/NI200800069A/es unknown
- 2006-10-16 CA CA2625871A patent/CA2625871C/fr not_active Expired - Fee Related
- 2006-10-16 CN CNA2006800389598A patent/CN101291672A/zh active Pending
- 2006-10-16 US US12/083,047 patent/US7981910B2/en active Active
- 2006-10-16 EP EP06817031A patent/EP1940393B1/fr active Active
-
2008
- 2008-03-06 ZA ZA200802104A patent/ZA200802104B/xx unknown
- 2008-03-25 IL IL190436A patent/IL190436A0/en unknown
- 2008-04-17 EC EC2008008384A patent/ECSP088384A/es unknown
- 2008-04-18 SV SV2008002876A patent/SV2009002876A/es not_active Application Discontinuation
- 2008-04-25 CR CR9931A patent/CR9931A/es unknown
- 2008-05-16 MA MA30932A patent/MA30201B1/fr unknown
- 2008-05-19 NO NO20082278A patent/NO20082278L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP5036722B2 (ja) | 2012-09-26 |
JP2009512704A (ja) | 2009-03-26 |
CN103724335A (zh) | 2014-04-16 |
KR20080059236A (ko) | 2008-06-26 |
AU2006304434A1 (en) | 2007-04-26 |
SV2009002876A (es) | 2009-02-19 |
WO2007047625A2 (fr) | 2007-04-26 |
US20090258913A1 (en) | 2009-10-15 |
CA2625871A1 (fr) | 2007-04-26 |
RU2008119842A (ru) | 2009-12-10 |
WO2007047625A3 (fr) | 2007-10-11 |
US7981910B2 (en) | 2011-07-19 |
BRPI0617501A2 (pt) | 2011-07-26 |
NO20082278L (no) | 2008-07-17 |
AU2006304434B2 (en) | 2012-04-05 |
CR9931A (es) | 2008-08-21 |
ECSP088384A (es) | 2008-05-30 |
EP1940393A2 (fr) | 2008-07-09 |
EP1940393A4 (fr) | 2008-12-17 |
CN101291672A (zh) | 2008-10-22 |
ZA200802104B (en) | 2009-08-26 |
CA2625871C (fr) | 2014-07-08 |
NI200800069A (es) | 2008-06-25 |
IL190436A0 (en) | 2008-12-29 |
EP1940393B1 (fr) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30201B1 (fr) | Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1 | |
MA27579A1 (fr) | Derives de triazole comme inhibiteurs de la 11-beta-hydroxysteroide-deshydrogenase 1 | |
MA27317A1 (fr) | Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie | |
EA202192684A1 (ru) | Агонисты glp-1r и их применения | |
EP1638947A4 (fr) | Derives de triazole utiles comme inhibiteurs de la 11-beta hydroxysteroide deshydrogenase-1 | |
ATE472542T1 (de) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
DK2021337T3 (da) | Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1 | |
DK2029529T3 (da) | Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1 | |
EA200801426A1 (ru) | ПРОИЗВОДНЫЕ 2-АДАМАНТИЛМОЧЕВИНЫ В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ 11β-HSD1 | |
EP1797034A4 (fr) | Composes de sulfonyle comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1 | |
ATE555081T1 (de) | Adamantyl-derivate als inhibitoren des 11-beta- hydroxysteroid-dehydrogenase-1-enzyms | |
CA2534221A1 (fr) | Carboxamides de pyrazole utilises comme inhibiteurs de la dehydrogenase-1 11-beta-hydroxysteroide | |
DK2035379T3 (da) | Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1 | |
SE0403006D0 (sv) | New compounds | |
ATE386715T1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
WO2007087150A3 (fr) | Derives de triazole en tant qu’inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1 | |
TNSN08405A1 (en) | Cyclohexylpyrazole - lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
MA30421B1 (fr) | Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1 | |
WO2007096763A3 (fr) | Pipéridinoylpyrrolidines en tant qu'agonistes du récepteur de la mélanocortine de type 4 | |
EA201001737A1 (ru) | Новые производные nip тиазола в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы-1 | |
EA201000751A1 (ru) | Производные 7-азаиндола в качестве селективных ингибиторов 11-бэта-гидроксистероида дегидрогеназа 1 типа | |
MX2009008773A (es) | Derivados de 3,4-dihidro-1,4-benzoxazina,3,4-dihidro-1,4-benzotiaz ina y 1,2,3,4-tetrahidro-quinoxalina como agonistas de adrenoreceptores alfa2c. | |
DE602005024539D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
DK1697306T3 (da) | Selektive peroxisomproliferatoraktiverede receptormodulatorer |